There's one line of math I find myself coming back to. G=H-TS. Gibbs Free Energy. It’s the equation that determines whether a molecule will actually stick to a protein, or drift right on by. Three simple terms, and they dictate whether a drug will work or not. I fell in love with math long before I understood why it would matter - multiplication tables felt like a secret kind of music, neat and definite in ways nothing else childhood ever seemed to be. But I fell hard for it the day I realized that a single line of math, small enough to fit on one line, could determine whether an answer would help someone dying or not. The real world can be messy, and math has no use for any of it, it can wait. What I love about math the most is the place where it's quiet, and structural - where you get beyond the part that everyone skips on their way to the "answer." In the graph neural network architecture I use for drug discovery, every single prediction is made via a message-passing function; hᵥ' = σ(W · Σhᵤ + b). It looks opaque until you realize it's an expression of one idea - each atom in the molecule hears from its neighbors, learns more about its own position, and updates its representation layer by layer until the molecule "knows" its shape. And it is completely unforgiving. Ninety-five percent correct is still wrong; a calculation 95% accurate will either send a good drug to the bin or have a chemist chasing a wrong lead for months. I used to find that rigor frightening, and now it's oddly comforting. When everything else in the world is built on a promise of something vague that may or may not exist, math at least guarantees me that if I'm wrong, I'm utterly wrong. And then will show me the calculation so I can find out why. And that's why I love it. It's not because it's beautiful, though I think math often is. It's not even because I think it's terribly useful, though it's changed the way I think about chemistry, economics, about everything. I love math because I think it's honest in a way not many things are, and I have found that each equation I sit with long enough always opens into something wider than the page it's on.

1. Three to four years back, at 3am in the morning, eyes blurring at the screen till they suddenly snapped into focus. Five boys in muted blue lights, a sound that didn't hit my ears first but my chest, and then the rush of being completely captivated. My back straight, replaying it four times before I could allow myself to sleep; the floor felt like it was tilting. 2. Soft, stubborn loyalty. We are MOA who wait through long gaps for a solo, tours we are not invited to, teasers we receive in the middle of the night – without becoming resentful, always there, sending hearts. MOA means unwavering commitment. 3. Completely, hopelessly Kang Taehyun. I remember the entire concert moving around him at a breakneck pace while he held a single note, blinking rarely; while all around was motion, he seemed suspended. His voice a low, aching melody against a face giving away absolutely nothing – my stomach plummeted each time. It was less like I chose him than he chose the small corner of my heart that remains silent. 4. Taehyun, no question. Some people get comfortable and don't need to try again. 5. "Chasing That Feeling." I can’t recall all the lyrics but I remember what it feels like: living in the moment just before something sweet becomes too overwhelming; it carries the hint of sweetness and the whisper of being close to something overwhelming without ever arriving at either-like wanting something and knowing you may or may not achieve it. Walking home in the dark with my chest tight, trying to embrace the longing for my future self and all that awaits me; the song acknowledges this longing. 6. Not yet and typing that out makes my fingertips ache. I've watched many fan cams of a roaring stadium,MOA in tears while waving their lightsticks, and yearned so fiercely that my hands grew cold. 7. The Chaos Chapter: FREEZE. The entire era was like glass cracking in slow motion; like frosted glass, like a moment in time frozen before breaking apart, like bodies stuck mid-fall, and like the choreography abruptly stopping into a pose. Everything became glass-sharp, brittle, and overwhelming in the best possible way, my hand cupping my mouth in awe of the artistry. 8. Honest to god, I am barely managing- I’m an international student who gets no aid or loan like FAFSA from the US; it's only the study loan, and it doesn't even account for the flights from India to the US nor other miscellaneous things that constantly run calculations in my mind. 9. The scholarship would be for what is not mentioned in the tuition bill: a flight home to see family during holidays, the initial moving expenses, the amount by which my loan falls short. It wouldn’t be helping my degree; it would help me actually be here to study for my degree. 10. I've seen them grow from nervous trainees on a tiny stage to headlining major festivals, and somewhere in their rise, I realized my own small progression matters too. They were never "ready" but they kept on showing up, take after take- and on those nights where nothing makes sense, where nothing seems close to being right, I recall that they showed up. All I have to do now is show up tomorrow. 11. I'm pursuing research on the brink of biology and computer science hoping that my studies may someday contribute to a faster drug discovery process for illnesses to which funding is never offered by anyone racing to develop cures, and- much like TXT showed me the value of years of commitment to their passion-I want to bring years of faithful research, even without immediate breakthroughs, in order to buy someone, someday, more time.

The flowers smelled wrong. This is the one detail I could not articulate then and cannot forget now. We were thirteen and sat in her living room and somebody had put fresh flowers on the table to make the room feel like itself - only they smelled like a lie in the air, while my best friend's shoulders shook, and I hugged her without the knowledge of what to say, since there was nothing to say. Her mother had just been diagnosed, and the word hung in the air, heavier than anything thirteen years of life had exposed me to. The flowers keptsmiling. Everything else had stopped. I didn’t know enough then. That’s what I know now. I didn’t know what inflammatory breast cancer meant, what the stages meant, what the treatment would do to her body, what questions her family should be asking and to whom. I was a child clinging to another child, while a woman we both loved experienced something enormous, and all I had to offer was proximity because I had nothing more. That absence - of knowledge, of access, of someone to translate the medical reality into something actionable, human - lingered. Her mother is still fighting. She has been fighting for years, with a fierceness that redefined the word for me. I have watched her maneuver a health system that necessitates the patients and their families to instantly become experts on imaging results, treatment protocols, clinical trial enrollment criteria, management of side effects, and countless other intricacies - while also carrying the immense emotional and psychological burden of a diagnosis that touches every element of a life. I have watched my best friend grow up too soon because people around her needed her to. What breast health education means to me is the difference between a family walking into a room alone, and walking in with someone who already knows the way. A breast health navigator. A lactation consultant who knows to flag certain signs. An imaging technician who sees something on a scan and instantly knows what to look for next and whom to contact. These aren't the extras. They are the people in a position to walk with a patient and her family through her most frightening moments, to say, “ I’ve traveled this path before, and you won’t walk it alone.” I am a neuroscientist, and my career is being built at the nexus of biological research and health tech. The focus of my research is in neurodegeneration and the potential for drugs to intervene earlier in the biological processes of disease. My career path and breast health are not separate: they represent the same central question asked in different spheres: How can we close the gap between what medicine knows and what patients and their families actually experience? Education is this bridge. The trained breast health professional not only holds the clinical expertise but also the ability to translate it, to humanize it - to sit across from a terrified woman and her equally terrified daughter and make the information intelligible, and the path forward clear. I still think of that living room sometimes: the flowers that smelled wrong. The futility of a presence unadorned with knowledge. It's in service of building bridges across that chasm, not just in the fields I research, but for any person receiving the news of a complex diagnosis. Annie Pringle lived a life dedicated to standing in that gap. This scholarship makes it possible to do so in her legacy. I will too.

My bedroom fluorescent light buzzes and flickers, then kicks on. It's 2am in Pitampura, Delhi, and the streets outside have finally fallen silent. On my screen is a table of proteomic markers from a Parkinson's disease model; rows and columns of numbers which somewhere within them represent the molecular profile of a mind collapsing in on itself. I'm 16 years old. I've been awake for 19 hours. And I've never been more certain about anything in my entire life. I grew up in a middle class family in Northwest Delhi, where ambition was not only a given, but also severely under-resourced, the gap between a good idea and the infrastructure required to implement it was everything. I saw people I grew up with struggle in healthcare systems that were chronically underfunded, over-burdened, and structurally flawed in such a way that prevented meaningful intervention until it was too late. I saw bright students hit inevitable ceilings, not because of their capabilities, but because of their lack of access to mentorship, research opportunities, or the networks that turn potential into reality. From early on I resolved that I would not be limited by these ceilings. I am pursuing Neuroscience at the University of California, San Diego because I see neurological disease as one of the most pressing unsolved questions in medicine today, and because I believe the tools we develop today determine what a decade of future patients will experience. While at Yale University School of Medicine, I was a research assistant for the past two years, working in two labs; in one, we identifiednovel mitochondrial protein markers for Parkinson’s disease models, and in another, we were studying the molecular mechanisms underlying neurodegeneration. I was at the Indian Institute of Science (IISc) in Bengaluru where I was working with mutations in DDX3X in a childhood brain cancer model. At sixteen, I co-founded a computational drug discovery platform that uses machine learning to accelerate the discovery of potentially new therapies, currently being used in Harvard Medical School and Yale University for pre-clinical trials. These accomplishments did not arise from the path of least resistance. They arose from my creating a path as I went along, starting from that one buzzing bedroom in Delhi, and reaching out toward the institutions and opportunities that weren't inherently designed for me to succeed. That experience of having to be a person who doesn’t automatically belong in the room, but enters anyway, and works harder than anyone else, fuels the impact I wish to make. My goal is to dedicate my career to the intersection of neuroscience and technology to develop new tools that bridge the gap between the lab and the clinic. But beyond the science, I want to devote my career to ensuring that the rooms I now enter, or build, will be more accessible to the students who come after me. I co-founded a global mentorship organization that has linked over a hundred students from underprivileged backgrounds to mentors across fifty different countries. I know exactly how one introduction, one individual stating "you belong here" can change the trajectory of a young person who has been told otherwise by every institutional signal around them. The world doesn't need more gatekeepers. It needs people who hold the door open. That is exactly what I intend to do with my career-and with my life.

It wasn’t when I was in the hospital that I really understood the cost of medicine. It was in a dataset. When I was sixteen, I worked remotely with the Jonas Lab at Yale School of Medicine on proteomic data for models of Parkinson's Disease. The numbers on my computer screen referred to individuals whose dopaminergic neurons were degenerating-an irreversible process that can be slowed by medicine, but not reversed, because the molecules upstream of the damage are not yet fully mapped. I studied DJ-1 expression levels, seeking molecular markers that would indicate mitochondrial damage before it began a chain reaction, and I found three. These are currently being incorporated into lab publications and might eventually allow doctors to diagnose Parkinson's earlier than before. It was this realization-that the gap between a molecular dataset and the quality of life of a patient is far narrower than we often think, and that someone has to be willing to do the work of bridging that gap-that motivated me. I study neuroscience because neurologic disease is one of medicine's most pressing and unsolved frontiers. Alzheimer's, Parkinson's, pediatric brain cancers: these conditions affect tens of millions and share a common mechanism. Clinical symptoms appear long after the damage has accumulated over years, even decades. All of my research has been geared towards narrowing this window. I've simulated the effect of DDX3X mutations on pediatric medulloblastoma at IISc Bengaluru, aiming to learn how single mutations in the genome alter the development of a child's brain. I've modeled alpha-synuclein fibril binding to synaptic proteins at Yale's Bierder Lab, creating a picture of neurodegenerative disease at the molecular level. The recurring theme: medicine needs better ways to detect biological signs earlier, more accurately, and across more individuals than it currently can. That's where I see myself making a contribution: not at the bedside, but in building the infrastructure for improved bedside medicine. I co-founded an AI-driven computational drug discovery platform at sixteen, aiming to speed up one aspect of this pipeline-the identification and validation of promising drug candidates. Harvard Medical School and Yale have active beta relationships with the platform, which is intended to translate molecular discoveries into treatments more quickly. In the long term, I am drawn to neurotechnology-studying how information is encoded and lost in the brain on a systems level, hoping that this knowledge will enable early intervention for neurodegenerative conditions. My ultimate goal is not only to gain knowledge, but to translate it into meaningful, practical tools for the medical field. The questions that motivate me are medical questions, even if my approach is computational: why do some patients decline faster than others? What are the earliest markers of neural deterioration? How can we develop instruments that allow clinicians to see what's happening in the brain years before current diagnostic capabilities. Medicine improves individual lives. The science that underlies medicine improves the lives of countless individuals. My ambition is to be at that second level-creating the tools, platforms, and knowledge to broaden the capabilities of medicine for future patients. That's the difference I intend to make.

The question that has followed me the longest hasn't come from a textbook. It arose the first time I saw a set of proteomic markers for a model of Parkinson's and knew that within those numbers was the molecular blueprint of a mind turning itself off-and that nobody had clearly mapped the meaning. I am seventeen and I have spent the past two years trying to answer why brains fail. I have studiedDJ-1 proteomic markers in Parkinson's disease models and identified three novel mitochondrial protein markers being incorporated into lab manuscripts at Yale School of Medicine. I have built computational models of alpha-synuclein fibril binding to synaptic proteins at the Bierder Lab, in pursuit of the mechanisms of neurodegeneration. I have run molecular dynamics simulations on DDX3X mutations, associated with childhood brain cancer, at RSI-India at IISc Bengaluru. At each point, I have explored a variation of the same question: how does an isolated molecular event-an abnormal protein, a mutated gene, a malfunctioning protein binding site-ripple out to encompass something as immense as loss of memory, movement, or a child's future? What fascinates me about the natural sciences is not certainty, but precision in its absence. A good experiment does not simply solve a problem. It elucidates the profound extent to which we are underinformed. My discovery of three mitochondrial protein markers did not answer all the questions aboutDJ-1 in Parkinson's; rather, it posed three new ones: why are those particular proteins disordered? What upstream trigger caused the disorganization? And can an intervention at that step alter the disease process? That chain of questions-each response unraveling further complexity-is the intellectual engine that drives my love for science. I am coming to UCSD this fall to study neuroscience because I believe that the central scientific endeavor of this century is deciphering how biological systems encode information-how physical neurons create thoughts, how molecular processes generate behavior, and how the physical domain of the cell becomes the experienced reality of being. I hope to join in this endeavor not just as a researcher, but as a builder. I co-founded a computational drug discovery company at sixteen and plan to start a neurotechnology firm after completing my Ph.D. Science and ambition need not be disjoint-science provides the fundamental building blocks for ambition to be realized. Natural science has shown me that the most truthful statement you can make about a complex system is "I don't know, yet," followed by "but this is what the evidence points toward," and finally, "and this is what I will test." This practice-restricting claims to the boundaries of data while relentlessly pursuing deeper understanding-is a lesson I want to carry into all my future work. The brain remains a mystery with more unknown unknowns than any other system I know. That prospect does not intimidate me. It is precisely the point.

The thing about mental health challenges, is they dont only affect one person in an entire family; they can effectively silence the whole house. In my case, my aunts manifested this the most starkly for me. Because they grew up under so much pressure in India, I watched as two of the smartest, liveliest women I ever knew, become faded under the weight of something no one in my community knew what to name. Since mental health was the "shadow issue," discussed only in whispers or not at all, they suffered a maze of anxiety and depression with no map to guide them. The experiences of watching my aunts suffered taught me the "Synthesis Wall" is more than just a scientific term, it is a social term. There is a deep and unaddressed gap between the biological phenomenon a person is experiencing and the language that the rest of a community uses to offer them assistance. These experiences instilled in me a sense of the world as a place in which the largest struggles, ironically, are the ones that you are told that you should conceal. This showed me how vital spoken empathy is in the midst of an individual's silent pain. This journey inspired me to direct my ambitions toward neuroscience and biophysics. I not only want to be a scientist, but I want to act as a translator for the invisible. It was the days that my aunts were their quietest that drove me during my research at Yale in which I examined protein signatures and the decline of mitochondria. I wanted to emerge from the "darkness," to search for the real molecular code of the brain. I came to understand that if we are able to unravel the predictable, determinant mechanisms in which our neurons converse with one another, we are then able to devise and create a far greater and more accessible path to healing. In the Cauwenberghs and Yates labs at UCSD, I intend to work toward bridging the gap between cutting edge neuroengineering and the realities of mental health struggles for individuals and their families. I will strive to use my position as both a founder and a researcher to demonstrate that these are not personal failures, but a biological puzzle that we can and must solve. I want to envision and then eventually bring to reality a world in which no individual from Pitampura to San Diego must endure the silent struggle, and in which the "spark" I observed fading within my aunts can be protected through science and illuminated through the shared stories we tell. Granting me this scholarship will allow me to concentrate my efforts, time and resources solely toward fulfilling this ambition.

In capturing "The Life of A Showgirl" and Taylor's growth, the most emotionally resonant performance isn't just a song, but the 10 minute "All Too Well" at the 64th Annual Grammy Awards. The emotional power of that performance comes from the sheer act of unvarnished, uncompromising narrative reclamation. That song was an artifact for years - a mythical 'hidden' track only within the fans' imaginations. By performing that song in full, unadulterated at that massive global stage, Taylor stepped beyond the pristine Showgirl into the jagged, raw reality of her own narrative. Watching her at the piano, her hair wild and her voice fracturing through the lines: "You kept me like a secret, but I kept you like an oath" is a testament to enduring emotional strength. It's moving because it validates female remembrance as women's true power. It's not just a song; it's an exorcism for anyone who has ever been hidden in their own narrative. A song is turned into a story of survival, legacy, and a brazen decision to occupy ten minutes of broadcast time where the world generally expects women only to occupy three. That is the Showgirl moment of all time. It is not because of the lights or the outfits, but because one of our icons' most radical actions is speaking her truth, no matter how her voice shakes. Because it's a reminder that we, too, are permitted to occupy space in our own stories, down to the last "Easter Egg" and the last broken heart.

1. About You (Identity & Background) I describe myself as a "Digital Architect," a persona that I forged from the hyper-competitive, standardized academic ecosystem in Delhi, India. My identity has been shaped by an education system that reduces ambition to a number on an exam; a result that instilled in me a stubborn belief in the value of intrinsic learning. An alumna of RSI-India and a black belt in Taekwondo-both experiences that demonstrated to me the inextricable link between discipline and innovation. My identity is anchored in "The Synthesis Wall" - a term I coined to refer to the chasm between scientific theory and physical realization. I am more than a student; I am a researcher dedicated to building the geometrical deep learning models required to ensure that life-saving drugs are not only design-ready, but manufacture-ready and thus, accessible to those not fortunate enough to inhabit the innovation elite. 2. Learning Across Cultures The shift from the CBSE curriculum in India to the high-stakes, complex world of research at Yale and Harvard has underscored to me that, while "science" is universal, "access" is culturally defined. I learned the art of making do with less through long nights running complex computations on a consumer-grade machine during monsoon power outages back home; I am learning now, at Harvard and Yale, the power of "building in public" and shared, iterative risk. As an international student, successfully navigating the bewildering labyrinth of visa applications and self-building professional connections from the ground up has taken me from a student following instructions to a leader building my own scaffolding. I have come to see my "outsider" status as a competitive advantage; it has allowed me to spot bottlenecks that more ingrained researchers take for granted. 3. Perspective & Growth The most impactful realization I have had to date is that discovery is not an act confined to the solo effort of the privileged, but rather a collective act of shared wonder. As a leader of ImmunoVa, a 250-person open-source research collective, my perspective has broadened from a singular focus on personal achievement to that of enabling others' discoveries. I am beginning to understand my value not solely as a coder, but as someone who can make code accessible to everyone. From a purely academic perspective, the hours spent in the Jonas Lab at Yale have taught me that "failure" in a simulation is nothing more than an opportunity to glean information from a more robust landscape of truth. From a personal perspective, I have learned that resilience isn't about surviving trauma; it's about the audacity to dream of a $2000 Inflection grant while confined to a cramped room in Pitampura, Delhi. 4. Education & Future Direction My long-term goal is to bring AI-native Synthera, my startup, to full maturity. I aspire to transform drug discovery from a gamble into a programmed certainty. Attending UC San Diego and working in the Cauwenberghs and Yates labs will allow me to bridge the gap between AI design and neuroengineering. This scholarship will act as a crucial bridge for my future: while I have secured non-dilutive R&D funding for my startup's computational demands, that funding cannot cover the personal academic infrastructure – the tuition, specialist hardware and living expenses – that allows an international student to survive. With this support, I can dedicate my full intellectual energies to the most obdurate problems in healthcare, ensuring my contribution to the field is limited only by the stubbornness of my scientific resolve and the power of my computational vision.

To make an impact on the world, you must first see where the "walls" are - where we stop being able to innovate because of high costs of entry, or rare tools. The wall, to me, is at the intersection of medicine and access. As a child growing up in the vibrant, yet unequal, expanse of Delhi, I quickly learned that a genius scientific breakthrough is worth nothing if you can't produce it or afford it. My intended impact is to break down the "Synthesis Wall," democratizing the very tools of drug discovery and disease diagnostics. My journey of giving began not in a lab, but in the digital trenches of open-source collaboration. I helped to lead ImmunoVa, a 250-person research collective dedicated to developing early-stage cancer diagnostic tools. By deliberately taking a non-profit, open-source path, I wanted to ensure that the predictive pipelines we developed-which would later go on to achieve 91% accuracy-would be usable by under-resourced communities shut out from elite medical data. I learned that true compassion in STEM doesn't just mean solving the problem; it means sharing the solution. This same selflessness fueled my work as the Director of R&D for the World Health Institute and Food Health Institute (WHI/FHI). While managing research for hundreds of students across 50 countries and orchestrating a UN FAO hackathon for food security, I learned that the most sustainable way to serve a community is by fostering the technical ambition of its youth. By connecting students with global mentors, I provided them the same "infrastructure of hope" I struggled to cobble together for myself as an undergraduate in India. Now I have the chance to scale this commitment at UCSD, with the support of the Cauwenberghs and Yates labs, to gain the technical resolution needed to tackle our neurodegeneration problems, and eventually lead Synthera. My vision for Synthera is a world that moves beyond chance when discovering new therapeutics and approaches it as a programmed certainty-where the "instruction manual" for a life-saving medication is available at the most impoverished reach, moving us toward a future where someone's location doesn't determine their life expectancy. I believe compassion is synonymous with engineering without reservations-the act of working until 4am to fix a simulation error because you know that getting there sooner means people will be saved faster, the decision to use a $2000 Inflection compute grant not for personal learning but to construct medicine "manufacture-ready" for the underserved. By funding my education, you support the vision that scientific discovery must be a communal endeavor; a legacy of daring innovation to benefit everyone, regardless of circumstances.

There were times in the quiet, humid Delhi monsoon where I’d prop my laptop on a stack of old textbooks, trying to keep it from leaking through the ceiling. I was seventeen, attempting to run the computational beast that is molecular docking, a task that required far more processing power than a consumer laptop was built for and often meant a fight against flickering power and the limitations of the machine. For most people in my community, education beyond basic literacy either represents an unattainable luxury, or a gamble the family can't afford to take-it’s either a present of financial stability or a potential, distant reward. For me, however, education has always been the only guarantee, the only way past the "Synthesis Wall": the gap between dreaming up a life-saving medicine and building one. Attending UCSD is the catalyst that will transform my work from theory to a physical reality. I aim to innovate the process of drug discovery by treating biology not as a system for stochastically discovering life-saving treatments, but an engineered one. However, to do this effectively I require access not only to my laptop and my unreliable Wi-Fi, but to the high-resolution mass spectrometry and neuroengineering facilities in the Yates and Cauwenberghs labs. University is the specialized ecosystem that I will need to validate the AI models I have already architected, to turn them into a "manufacture-ready" therapeutics. Without that university environment, all I have is a digital blueprint; with it, I have a tangible treatment that could save lives. The way I intend to make a difference rests on a core principle: science cannot remain a lonely effort for the privileged few. I have already started to build that reality by founding ImmunoVa, an open-source research collective I led to democratize the process of cancer diagnosis. By coordinating a community of 250 researchers around the world to build diagnostic models, I proved we can accelerate medicine by de-elitizing and breaking down the "gatekept" world of top-tier data; the way I intend to do so is on an even larger scale with Synthera, an AI-native startup. It is my intention to build an infrastructure of drug discovery as sustainable as it is reliable, ensuring access to treatments isn't tied to a financial status or geographical location. However, this plan is by no means without its significant financial obstacles. As one of six in a household where my father is the sole provider, my relocation to an international university will bring an exorbitant financial weight with it. While I was fortunate enough to secure a $2000 Inflection compute grant for my research, the funding has been limited specifically to R&D processing on NVIDIA H100 clusters and has done little to support my immediate need for the personal academic infrastructure-the books, lab fees, and day-to-day supplies-that will sustain my time at university. A scholarship of this nature will do much more than simply ease my financial burden; it will be an investment in a scientist who has proven herself resourceful and efficient despite the significant constraints of her circumstances. I will be able to enter the laboratory at UCSD on my first day ready to contribute not to the funding concerns of a developing nation, but to the science of neurodegeneration and the ethics of access for all. Your support will champion the goal of universal medicine, engineered by those of us who know the price of being outside the door.

Living in the heart of Delhi taught me one very critical thing: resourcefulness wasn't a matter of choice; it was a matter of survival. It was a particularly humid monsoon Tuesday, and my street in Pitampura had turned into a river, and I was 16, huddled over my laptop perched on a pile of encyclopedias (to escape the ceiling leak), trying to run a molecular docking simulation while the power flickered like a rhythmic pulse of infrastructure breakdown. While the rest of the neighborhood used the rain as an excuse to stop and wait for the water to recede, in the dim, flickering haze of my room, I realized that I couldn't afford to wait for the "ideal" environment for my dreams to take shape. I had to engineer the circumstances myself, within the storm itself. Most of my community learn how to survive within the system, how to navigate the ruthless competitiveness of CBSE and find solace in the pre-defined path of medicine or engineering. Survival is a defensive stance. But for me, "dreaming" became a radical act of offense. It meant spending nights on open-source forums teaching myself biophysical chemistry that wasn't on my school curriculum, it meant cold-emailing professors across the ocean until I had landed myself a research position at Yale, as a girl who had never been outside of India, I was virtually traveling through the protein structures of neurodegenerative disease, my first trip being a journey not across borders but across knowledge. It is here at the University of California, San Diego (UCSD) that I feel I have moved beyond merely "surviving" the system to truly owning my story. Travel in the true sense of the word is perhaps the most courageous intellectual leap of faith. By leaving for the U.S., I have intentionally shed the comfort blanket of my family, my language, the streets I know by heart; I am embracing being a perpetual outsider because the friction born from the outside experience is what will force growth and innovation. At UCSD I won't just be a student; I will be a researcher finally able to step into the Cauwenberghs and Yates labs and physically interact with the equipment I had only previously seen on a screen. As I now prepare to depart in September of 2026, I don't plan on simply visiting the U.S.; I want to become immersed in the high-stakes environment of San Diego's biotech frontier, gaining a perspective that only leaving the world you've always known can achieve. I am shedding the "monsoon logic" and preparing to embrace the deterministic creation where I will build tools to bridge the "Synthesis Wall" for patients across the globe.

I choose a career path that sits between public health and innovation in the nonprofit sector because I deeply believe that cutting edge discoveries of science shouldn't be dictated by a persons economic standing, and it shouldn’t be out of reach due to their geographic coordinates. It’s this notion of medicine as a privilege rather than a right that made my academic passion for computational biophysics into my raison d’etre. I will be committed to using technology to promote social equity in medicine-that the discoveries in medicine tomorrow will be built for everyone rather than for profit. The clearest example of my passion for this cause is Immunova, the open-source 250-person research collective I led to bring early-stage cancer diagnostics to everyone. I developed pipelines that yielded cancer predicting models with 91% accuracy and we were a finalist in MICCAI, a top medical imaging conference. The fact that Immunova was open-source ensured that scientific barriers and data 'paywalls' to advanced diagnostics wouldn't exclude under-resourced people from accessing these high-level diagnostic tools. For me, the nonprofit sector is the only space that can uphold such extreme transparency, and I will strive to develop environments where it can thrive. My drive for impacting global resource insecurity spans across Diagnostics and has translated into my role as the Director of R & D for the World Health Institute and Food Health Institute (WHI/FHI), where I mentored over 500 students across 50 different countries in research and facilitated a UN FAO Hackathon on food security. These experiences revealed that true nonprofit impact must take on a "global first" attitude. By using my experience as a Borlaug scholar, I was able to facilitate the connections between over 100 students with global mentors to help increase the speed of advancement in global healthcare. Through the rigor of UC San Diego’s undergraduate programs and my work with both Cauwenberghs and Yates Labs, I hope to bridge high level laboratory discovery with community facing public health and medicine. Specifically, I intend to obtain the technical resolution to answer complex medical 'bottlenecks' while staying true to a public health mission to bring research to the masses. I see my career trajectory moving forward not only to provide the technical and collaborative space for science to expand its reach beyond profit and privileged groups, but I see myself working in a way that brings advanced science to every corner of the world.

Indian heritage for me isn't just a faraway ancestry; it is literally in every aspect of my upbringing in the bustling, high-stress world of Delhi. My entire childhood was spent running through the streets of Pitampura, with my nostrils filled with street food, and my mind with academic expectation. My roots are in the capital since I was born in 2009 to a lineage deep within the capital; the only hope, I was told, was my education. My heritage makes me the scientist who regards science as a collective effort: a lesson I learned from my grandfather as we sat on a park bench during our evening walk, and my community which constantly shared knowledge. This heritage drove me to strive in the stringent CBSE curriculum, but also to look beyond it. Leveraging my surroundings, I competed for, and among the 31 individuals chosen out of 5000, joined Research Science Institute (RSI-India) at Indian Institute of Science, where I pursued molecular dynamics analysis on childhood cancer proteins, converting my heritage of hard work into a technical pursuit. My Indian heritage instilled me with the concept that discovery is "a shared act of wonder"; the same philosophy that led me to develop open-source diagnostic tools for the underprivileged as a leader of online communities. Nonetheless, my journey to my undergraduate education in the United States at UC San Diego comes with its own financial struggles. My father supports a household of six – with my mother, younger brother and relatives all dependent on the earnings from his business owner profession-meaning his two incomes need to be stretched across six mouths, making an international education, with its astronomical price, an immense liability, which is necessitating substantial student loans. I have shown technical aptitude in procuring non-dilutive resources like a $2000 Inflection compute grant to further my startup; however, this funding cannot be applied toward tuition or other living expenses as it is strictly reserved for R&D processing on NVIDIA H100 clusters. This scholarship would be my lifeline, freeing up my parents from significant loan pressure, and allow me to concentrate solely on my research in the Cauwenberghs and Yates labs, starting on day one, making my Delhi-based dreams tangible through the U.S. Labs.

"Begin the morning by saying to thyself, I shall meet with the busy-body, the ungrateful, arrogant, deceitful, envious, unsocial. All these things happen to them by reason of their ignorance of what is good and evil. But I who have seen the nature of the good that it is beautiful, and of the bad that it is ugly... I can neither be injured by any of them, for no one can fix on me what is ugly, nor can I be angry with my kinsman, nor hate him." > — Marcus Aurelius, Meditations, Book II.1 Here, in what many consider his greatest meditation, Marcus argues that humanity's tendency toward conflict is a product of moral blindness, and the wise man's response is not to seek an external buffer but an internal fortification of the soul that is impervious to the malice of others, an acceptance of others' cruelty with a loving, duty-bound empathy for a shared humanity. Aurelius doesn't suggest a morning ritual filled with affirmation and sunny outlooks, but a clear-eyed, clinical encounter with the harsh realities that humanity will present to the emperor. In detailing the 'busybody', the 'ungrateful man,' and the 'arrogant man', he is engaging in prolepsis (the anticipation of future troubles) and demonstrating a key tenant that humanity’s suffering is not always the event itself, but the surprise of the event. Most people enter into a silent, false contract with the world that people will treat them with kindness; when this implicit contract is broken they feel 'injured'. Aurelius' tears up the contract at dawn. In saying that human drive and ambition 'depend on nothing,' he shows that it is not favorable circumstances but difficult ones that allow the intelligent to demonstrate this quality. Reading closely, this 'list' is not an insult to humanity but an act of self-protection. He states these are as predictable as nature: 'These are as much effects as they are causes.' Perhaps the most important insight from this selection is Aurelius' answer for why men behave so badly: their 'ignorance of what is good and bad'. This is the same as Socrates' claim that no one does wrong willingly. An uninitiated reader might see the 'deceitful man' as an enemy to be vanquished. A closer reading, however, sees the deceitful man as apatient with a visual defect-a cataract of the soul that will not allow them to 'see' the harm they are doing themselves. Changing the dynamic from threat to pity allows the leader to remain 'impactful' and avoid petty, wasteful revenge. This also brings us to Aurelius' definition of vice and virtue as 'beauty' and 'ugliness'. The ability to 'see' something that is 'ugly' does not make you 'ugly'. He says no one can "fix" anything "ugly" on him; the self is sovereign. While you cannot control what another does to your body, your reputation, or your wealth, you have absolute power over their impact on your soul if you refuse to grant them access. The 'underlying' idea here is a rejection of the victim concept. If you feel insulted, you are cooperating with the insulter; if you feel 'injured' by the 'ungrateful' man, you have let his 'ignorance' govern your emotional state. His goal is an internal, untroubled, nature-based response to everything. He closes with an impossible stipulation-he will not hate any man. Instead, the wrongdoer is his 'kinsman.' According to the Stoic idea of Oikeisis (fitting oneself to the world, self-attachment to the whole), we are all part of one 'cosmopolis' or world-citzenry; to hate any man is to attack the structure of reality. He uses a metaphor elsewhere of upper and lower teeth; they both operate against one another, but remain part of the same jaw. This can lead to social cohesion. 'Driving' means recognizing that, as a 'social animal,' one cannot be upset with man for simply being man; hating the ungrateful man would be as foolish as hating a stone for being hard or fire for being hot. The most meaningful implication of this meditation to the 'ambitious' student is not that of external accomplishment, but the redefinition of achievement; it is simply the quality that cannot be taken from you. In this intimate reading of the emperor's mind we see that his 'driving' was not a relentless need to control external affairs, but a relentless effort to control himself and rid himself of his anger. And in doing so, he shows that perhaps the 'impact' we have as human beings lies in remaining 'beautiful' to the 'ugly' and proving that the spirit is the creator of its own response.

The complexity of neurodegenerative diseases is typically framed in numbers – millions of diagnoses, billions spent on research – but for me, it began as a slow, agonizing destruction of the woman who was the foundation of my family's history. She was the keeper of our Indian heritage, remembering everyone’s birthday, every story about our ancestors, and every nuance of our community’s traditions. Witnessing her mind erode to Alzheimer's was like watching a living library disappear, and this personal tragedy ignited my academic journey and fueled my scientific ambition to enter the labs at Yale School of Medicine in order to fight the mechanism that stole my aunt.The pain of her illness profoundly impacted my family; we transitioned from sharing stories to existing within a "space of anticipatory grief" in which we grieved for her while she was still physically present. I came to realize that dementia has a dual impact; in addition to the patient suffering the loss of self, a 'caregiver's shadow' can cast the same amount of devastating loss upon the family. Seeing her inability to recognize her own children made me acutely aware that her loss of memory was actually a theft of her very identity. I felt compelled not just to witness her suffering but to comprehend the physical mechanisms that were taking her from us.It was this visceral understanding of suffering that prompted my transition into research. As a Research Intern at the Yale School of Medicine, the questions my aunt's diagnosis raised drove me to the Jonas Lab where I analyzed DJ-1 proteomics through the complex computation of MaxQuant and Python. I wanted to see the molecular trigger behind her suffering, not just the outcome. I successfully pinpointed three proteins linked to mitochondrial decline – a major player in neurodegenerative diseases. Contributing the findings that I uncovered for this data to a lab manuscript felt like a form of recovery, using the science I now commanded to regain a part of what I felt had been taken. I then continued my work at the Bierder Lab at Yale where I used PyRx and Chimera to model alpha-synuclein binding, the primary culprit of dementia-related protein aggregation. By successfully identifying 12 possible binding sites and directing 3 toward experimental screens I could clearly visualize the "stubborn molecules" of the disease as not unbeatable enemies but as solvable engineering challenges. This research revealed the importance of overcoming the "Synthesis Wall"-the critical gap between identification of a biological problem and the development of a marketable product. Now, my focus is entirely on breaking down this wall between groundbreaking research and easily accessible therapeutics, and as I begin my journey in the Cauwenberghs and Yates labs at the University of California San Diego, I draw upon the memory of my aunt as the most powerful driver of my own ambition to lead Synthera, using the power of my own artificial intelligence, BindAI, to stop the painful vanishing act that robbed my family of so much history.I plan to pursue a career in medical research driven by my firsthand experience of how debilitating the passage of time can be in the field of medicine and the extreme costs that inaction has, and I am now committed to building something with the power to end the suffering I witnessed within my family and on the part of so many others that I've come to know.

The start of my fascination with science came not with a success but with a spectacular failure. At 3:04 in the morning the red text flashed up on my laptop screen-the frantic pulse of a crashed simulation. I had been attempting to model molecular interactions on a drug discovery platform I'd spent the last months constructing, and it had finally thrown a tantrum. In the stillness of my Delhi room, I suddenly understood that biochemistry wasn't a fact sheet to be memorized; it was a frantic dialogue with the unknown, an extremely high stakes, highly competitive guessing game. And I became fascinated with simulating "stubborn" molecules precisely because I finally understood that the laws of physics weren't barriers, they were a code that could be optimized. That need to turn "static data into something alive" has characterized my trajectory. I saw a fundamental bottleneck in modern medicine-a “Synthesis Wall” that limited our ability to physically manifest the potential cures that AI could only predict. I reject “theoretical” as a final destination, and my goal is to transform drug discovery from an experimental game of chance to a process of deterministic manufacture. It was this imperative that sent me to the Research Science Institute (RSI-India) at the Indian Institute of Science, where I was one of 31 selected students out of a pool of 5,000 to research medulloblastoma. I spent my days and nights waiting for access to GPUs and my waking hours dismantling protein mutations in a desperate bid to take what I knew from the textbooks and turn it into understanding of how to stop pediatric cancer. The greatest adversity I’ve faced is the spatial and systemic disconnect that the lack of access to the finest technical resources affords. Coming from a pressure-cooker academic environment, I became my own engineer-pursuing opportunities to validate my work at labs at Harvard and Yale completely on my own. More than once I have found myself the only woman in highly specialized technical settings, and it is this experience that solidified my desire to overcome the mentorship vacuum in science. When I found that discovery itself was being gated, I took leadership of an open-source research community of 250 people and proved that diversity in STEM isn’t a statistic, it’s a necessary condition for solving problems that the establishment has failed to see. I measure my success not in papers I've written, but in tools I’ve built that are now being used. Whether it's my managing an Inflection compute grant to accelerate complex simulations or being recognized as a Borlaug Scholar for using technology to combat food security issues, my drive is the same. I'm going to the U.S. Not to get a diploma, but to hit the ground running at the Cauwenberghs and Yates labs at UCSD and to join them in this fight from day one. I’m coming to the U.S. To ensure that the breakthroughs of the next decade in medicine are born not just from curiosity, but from unadulterated, raw, scientific hunger and the engineering rigor to turn the "impossible" into something ready for manufacture.

It was not in a lecture hall, but at 3:04 am staring at a red error filled screen that I first saw the "Synthesis Wall". Standing in the stillness, a budding researcher immersed in the intricate world of computational biophysics, I felt the same weight Maggie Kwiecien must have experienced when she first landed in the US, alone, in 2015. This is the weight of being the first person to tread in uncharted waters, with nothing more than an iron will and an intelligent mind. Like Maggie, I have never shied away from physical or intellectual discomfort. My journey toward discovery has included diving beneath the ocean's surface; the deafening quiet of the water honed my senses and taught me how fear could blossom into wonder. It is that same thirst for exploring the unknown that has driven me in the lab, where I have spent many late nights awaiting precious GPU hours to decode the protein interactions responsible for pediatric medulloblastoma and cellular senescence. Maggie's "Boldest Bold" spirit resonated deeply with me; science is not something I just study, it is something I fight for. Maggie was known to be an exceptionally intellectually bold engineer, someone who would readily debate the merits of scientific claims. In an earlier stage of my career, leading a global research collective at ImmunoVa, I discovered a similar fervor during a particularly intense argument over whether or not to release early predictive results regarding drug toxicity. While the speed of publication was a primary concern for my peers, my emphasis on the integrity of our data-refining our models until we could confidently back our results-resonated with Maggie’s insistence on always striving for the truth. It is this pursuit of veracity, above all else, that I will bring to my role as co-founder of Synthera, where I will leverage AI to bridge the void between AI-designed molecules and physical reality. My journey has taken me from the highly competitive environment of the CBSE classroom in Delhi to the labs of both Yale and the Indian Institute of Science, always with the underlying goal of becoming an expert in whatever field I pursued. Whether that expertise has come from mastering molecular dynamics through a rigorous RSI-India fellowship, or from skillfully managing over $2000 of Inflection compute time on NVIDIA H100 clusters, I have consistently worked to maximize the resources available to me to propel my own, and women in STEM's, abilities to their furthest limits. As I look forward to joining the labs of Cauwenberghs and Yates at UCSD, this scholarship is more than just financial support-it is a mandate to carry forth Maggie's example of courage and fortitude. I am an international woman pursuing the 'Synthesis Wall,' and my goal with this opportunity is to foster the democratization of scientific discovery. Maggie Kwiecien demonstrated that the boldness of one remarkable engineer can move mountains; I intend to honor her by ensuring that the next decade of medical progress is built on the same audacious, unadulterated pursuit of the unknown.

At 3:04 in the morning my apartment was really quiet except for the sound of my laptop fan. The screen was filled with red because I had been running the simulation for six hours. I did not close my laptop. I got up. Made some tea. There is a kind of frustration that comes with working in computational biology. It is not the frustration of being stuck. Of realizing you have been asking the wrong question the whole time. That night I stopped trying to force the DDX3X protein to behave the way my model expected it to. I started wondering what it was actually doing. It may sound like a thing but it changed everything about how I work. I grew up in Delhi, where school was very competitive. We were graded on marks and ranks and outcomes. I was good at it. I was always more interested in understanding the basics of things. Why does this molecule behave in a way? What does it mean that it resists every simulation until you stop trying to control it? I chose biophysics because it is a field that requires rigorous thinking but also provides complex answers that surprise you. At RSI-India I was one of 31 people selected from 5,000 applicants. I worked on running simulations and analyzing proteins connected to medulloblastoma. At Yale in the Jonas and Bierder Labs I validated AI models against data and found three proteins tied to mitochondrial decline whose binding sites were actually used in lab tests. Each of these accomplishments felt like an achievement and more like a door opening to something bigger. Synthera came from a recurring problem: AI-designed molecules kept failing not because the models were wrong. Because there was a gap between computation and reality. So we built a bridge between the two. ImmunoVa, our source diagnostic platform became a finalist at MICCAI and attracted a community of 250 researchers from over 50 countries. We made it open-source not because we were idealistic. Because it was the logical thing to do. Breakthroughs happen faster when more people have access to the tools. I have usually been the woman in the room especially in technical and deep-tech spaces. At first this felt like something I needed to overcome. Now it just feels like information. It tells me which rooms need to change and what I want to build. The Cauwenberghs and Yates labs at UCSD are where I want to take my work. The questions I am asking. About decline, about the gap between simulation and reality about what drug discovery looks like when it becomes more engineering than trial and error. Feel like a perfect fit for what those labs are working on. The practical reality is simple: the compute grants I have received including $2000 in H100 access are for research and development. They do not cover living expenses, like books, hardware or rent when you are moving to a place to start a PhD. This scholarship would mean I can focus on the science from day one. That is all I am asking for. I have been doing this work for a time even before I had the credentials to justify it. I plan to keep doing it long after the credentials stop mattering.